title: Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.
abstract: OBJECTIVE
  The combination of chemotherapy and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is consistently being used as first- and second-line treatment in patients with metastatic colorectal cancer (mCRC). There is little data of the activity of bevacizumab in chemorefractory mCRC patients. The aim of this retrospective single center study was to evaluate the activity of bevacizumab combined with chemotherapy in this study population.
  
  
  METHODS
  Forty-six consecutive mCRC patients treated in the University Hospital Gasthuisberg (Leuven, Belgium) receiving bevacizumab in advanced lines following failure of conventional chemotherapy were included in this study. Treatment regimen consisted of bevacizumab 5 mg/kg in combination with leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) or leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI).
  
  
  RESULTS
  Bevacizumab plus chemotherapy was used in third-line treatment in eight (17%) patients and in fourth-line treatment or more in 38 patients (83%). All patients previously failed irinotecan-based chemotherapy, 44 (96%) failed oxaliplatin-based regimens, and 40 (87%) failed treatment with cetuximab. Bevacizumab was given in combination with irinotecan-based chemotherapy in 36 patients, oxaliplatin-based chemotherapy in nine patients, and with single agent 5-fluorouracil in one patient. Objective response was demonstrated in ten patients (22%) and disease control in 38 (83%) with a median progression-free survival of 8.9 months and a median overall survival of 13.8 months. Only four patients experienced grade III and above bevacizumab-related toxicity.
  
  
  CONCLUSIONS
  Taking into account the retrospective nature of the study which can influence the selection of patients, bevacizumab given in advanced lines after failure of conventional chemotherapy and antiepidermal growth factor receptor agents can result in high disease control rates in patients with mCRC.
authors: Gastrointestinal Malignancies Service, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; ; Department of Gastroenterology, Digestive Oncology Unit, University Hospitals Leuven, Leuven, Belgium;
authors: Ravit
authors: R
authors: Geva
authors: Loredana
authors: L
authors: Vecchione
authors: Sabine
authors: S
authors: Tejpar
authors: Hubert
authors: H
authors: Piessevaux
authors: Eric
authors: E
authors: Van Cutsem
authors: Hans
authors: H
authors: Prenen
keywords: bevacizumab; chemorefractory; colorectal cancer
references: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references: 21685461
references: Nature. 1993 Apr 29;362(6423):841-4
references: 7683111
references: J Clin Oncol. 2000 Aug;18(16):2938-47
references: 10944126
references: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references: 17442997
references: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references: 18316791
references: Science. 2005 Jan 7;307(5706):58-62
references: 15637262
references: Am J Clin Oncol. 2011 Dec;34(6):573-80
references: 21217399
references: Cancer. 2009 Oct 15;115(20):4849-56
references: 19626652
references: BMC Cancer. 2009 Sep 28;9:347
references: 19785749
references: N Engl J Med. 2009 Apr 2;360(14):1408-17
references: 19339720
references: Cancer Res. 1997 Oct 15;57(20):4593-9
references: 9377574
references: Ann Oncol. 2009 Nov;20(11):1842-7
references: 19406901
references: J Clin Oncol. 2006 Jul 20;24(21):3354-60
references: 16849749
references: J Clin Oncol. 2008 Apr 20;26(12):2013-9
references: 18421054
references: Lancet. 2000 Mar 25;355(9209):1041-7
references: 10744089
references: J Clin Oncol. 2004 Jan 1;22(1):23-30
references: 14665611
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: J Clin Oncol. 2008 Apr 20;26(12):2006-12
references: 18421053
references: Oncologist. 2012;17(8):1039-50
references: 22773560
references: Cancer Res. 2001 Jul 1;61(13):5090-101
references: 11431346
references: Int J Cancer. 2011 Jul 1;129(1):245-55
references: 21170960
references: Med Oncol. 2009;26(1):32-7
references: 18498064
references: N Engl J Med. 2003 Jul 31;349(5):427-34
references: 12890841
references: J Clin Oncol. 2011 May 20;29(15):2011-9
references: 21502544
references: J Clin Oncol. 2005 Jun 1;23(16):3706-12
references: 15867200
references: N Engl J Med. 2000 Sep 28;343(13):905-14
references: 11006366
references: Oncologist. 2000;5 Suppl 1:11-5
references: 10804085
references: N Engl J Med. 2004 Jul 22;351(4):337-45
references: 15269313
references: Clin Cancer Res. 2008 Aug 15;14(16):5069-80
references: 18694994
references: Biologics. 2008 Mar;2(1):53-9
references: 19707427